We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Bispecific antibodies against the main SARS-CoV-2 variants of concern: an effective strategy.
- Authors
Pascual-Galván, D.; Hernández-Rivera, V. D.; Sansanwal, D.; Rosas-Ramírez, E. D.; Vázquez-Leyva, S. K.; Salinas-Trujano, J. R.; Pérez-Tapia, S. M.; Pedraza-Escalona, M. M.
- Abstract
COVID-19 caused by SARS-CoV-2, emerged as a global pandemic, highlighting the RNA virus’s rapid mutation rate, in special affecting the Spike (S) protein, which is crucial in the binding with the host cell receptor. As a result, variants of concern (VOCs) appeared with the ability to escape from the immune response. In contrast, several monoclonal antibodies were used as treatment against COVID-19, but they failed through the time, because they lost the binding capacity. We developed bispecific antibodies from a group of human monoclonal antibodies able to recognize different RBD epitopes using the Epstein-Barr virus immortalization human B cells method. The variable regions of the heavy and light chains of these antibodies were amplified, sequenced, and the germlines were analyzed. The constructions of heterodimers VHS57G9-(G4S)4linker-VLS57G9-K6/K9linkerVHP7F8-(G4S)4linker-VLP7F8, and VHS56G9-(G4S)4linker-VLS56G9-K6/ K9linker-VHG6E8-(G4S)4linker-VLG6E8 were cloned in the pFUSEss-CHIg-hG1. Each dimer was expressed in Expi293 cells. These were purified by affinity chromatography with protein A. We evaluated the binding affinity and neutralization capacity compared with the monomers used as controls. These bispecific antibodies against SARS-CoV-2 increased the constant affinity and neutralizing properties. Also, their capacity against VOCs enhanced broadly.
- Publication
Veterinaria México OA, 2024, Vol 11, p50
- ISSN
2448-6760
- Publication type
Article
- DOI
10.22201/fmvz.24486760e.2024.1305